TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice